[go: up one dir, main page]

WO2004028480A3 - Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof - Google Patents

Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof Download PDF

Info

Publication number
WO2004028480A3
WO2004028480A3 PCT/US2003/031005 US0331005W WO2004028480A3 WO 2004028480 A3 WO2004028480 A3 WO 2004028480A3 US 0331005 W US0331005 W US 0331005W WO 2004028480 A3 WO2004028480 A3 WO 2004028480A3
Authority
WO
WIPO (PCT)
Prior art keywords
cftr
cystic fibrosis
thiazolidinone
methods
fibrosis transmembrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/031005
Other languages
French (fr)
Other versions
WO2004028480A2 (en
Inventor
Alan Verkman
Tonghui Ma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/262,573 external-priority patent/US20040063695A1/en
Priority to MXPA05003366A priority Critical patent/MXPA05003366A/en
Priority to CA2500498A priority patent/CA2500498C/en
Priority to JP2004540305A priority patent/JP4977319B2/en
Priority to AP2005003292A priority patent/AP2005003292A0/en
Priority to NZ538809A priority patent/NZ538809A/en
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Priority to AU2003277162A priority patent/AU2003277162C1/en
Priority to EP03798805A priority patent/EP1549321A4/en
Priority to EA200500583A priority patent/EA009847B1/en
Priority to BR0314943-9A priority patent/BR0314943A/en
Publication of WO2004028480A2 publication Critical patent/WO2004028480A2/en
Publication of WO2004028480A3 publication Critical patent/WO2004028480A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more thiazolidinone compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a thiazolidinone compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a thiazolidinone compound. In addition, the invention features a non-human animal model of CFTR-mediated disease which model is produced by administration of a thiazolidinone compound to a non-human animal in an amount sufficient to inhibit CFTR.
PCT/US2003/031005 2002-09-30 2003-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof Ceased WO2004028480A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BR0314943-9A BR0314943A (en) 2002-09-30 2003-09-30 Cystic Fibrosis Transmembrane Conductance Regulatory Protein Inhibitors and Uses of These
EP03798805A EP1549321A4 (en) 2002-09-30 2003-09-30 PROTEIN INHIBITORS REGULATING TRANSMEMBRANE PERMEABILITY OF CYSTIC FIBROSIS (CFTR) AND SCREENING
JP2004540305A JP4977319B2 (en) 2002-09-30 2003-09-30 Cystic fibrosis membrane conductance regulator protein inhibitor and method of use thereof
AP2005003292A AP2005003292A0 (en) 2002-09-30 2003-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
NZ538809A NZ538809A (en) 2002-09-30 2003-09-30 Thiazolidinone cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
MXPA05003366A MXPA05003366A (en) 2002-09-30 2003-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof.
AU2003277162A AU2003277162C1 (en) 2002-09-30 2003-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
CA2500498A CA2500498C (en) 2002-09-30 2003-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
EA200500583A EA009847B1 (en) 2002-09-30 2003-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/262,573 2002-09-30
US10/262,573 US20040063695A1 (en) 2002-09-30 2002-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
US48025303P 2003-06-20 2003-06-20
US60/480,253 2003-06-20

Publications (2)

Publication Number Publication Date
WO2004028480A2 WO2004028480A2 (en) 2004-04-08
WO2004028480A3 true WO2004028480A3 (en) 2004-07-01

Family

ID=32044981

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/031005 Ceased WO2004028480A2 (en) 2002-09-30 2003-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof

Country Status (13)

Country Link
EP (1) EP1549321A4 (en)
JP (1) JP4977319B2 (en)
KR (1) KR20050061501A (en)
CN (1) CN100356922C (en)
AP (1) AP2005003292A0 (en)
AU (1) AU2003277162C1 (en)
BR (1) BR0314943A (en)
CA (1) CA2500498C (en)
EA (1) EA009847B1 (en)
MX (1) MXPA05003366A (en)
NZ (1) NZ538809A (en)
PL (1) PL376147A1 (en)
WO (1) WO2004028480A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8952049B2 (en) 2006-04-07 2015-02-10 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
ES2882684T3 (en) 2006-04-07 2021-12-02 Vertex Pharma Preparation of transporter modulators from the ATP-binding cassette
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
BRPI0809498A2 (en) 2007-04-02 2014-09-23 Inst Oneworld Health CFTR INHIBITOR COMPOUNDS AND THEIR USES
ES2578735T3 (en) * 2007-08-24 2016-07-29 Vertex Pharmaceuticals Incorporated Isothiazolopyridinones useful for the treatment of (among others) cystic fibrosis
EP2578571B1 (en) 2007-11-16 2015-09-16 Vertex Pharmaceuticals Incorporated Isoquinoline modulators of ATP-binding cassette transporters
CN103626744B (en) 2007-12-07 2016-05-11 沃泰克斯药物股份有限公司 The benzoic solid form of 3-(6-(1-(2,2-difluoro benzo [D] [1,3] dioxole-5-yl) cyclopropane formamido group)-3-picoline-2-yl)
EP2279029A2 (en) * 2008-03-25 2011-02-02 The Regents of the University of California Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator
PT2615085E (en) 2008-03-31 2015-10-09 Vertex Pharma Pyridyl derivatives as cftr modulators
WO2009131951A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US8207205B2 (en) 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
WO2010033626A1 (en) * 2008-09-19 2010-03-25 Institute For Oneworld Health Compounds, compositions and methods comprising imidazole and triazole derivatives
US8343976B2 (en) 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
EP2490696A1 (en) * 2009-10-20 2012-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of disorders of glucose homeostasis
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
ES2845449T3 (en) 2010-03-25 2021-07-26 Vertex Pharma Solid amorphous dispersion of (R) -1 (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) -N- (1- (2,3-dihydroxypropyl) -6-fluoro-2 (1-hydroxy-2-methylpropan-2-yl) -1h-indol-5yl) -cyclopropanecarboxamide
EP2555755B2 (en) 2010-04-07 2019-07-10 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
AR081069A1 (en) 2010-04-07 2012-06-06 Vertex Pharma SOLID FORMS OF ACID 3- (6- (1- (2,2-DIFLUORBENZO [D] [1,3] DIOXOL-5-IL) CYCLOPROPANCARBOXAMIDE) -3-METHYLPIRIDIN-2-IL) BENZOIC
RU2569678C2 (en) 2010-04-22 2015-11-27 Вертекс Фармасьютикалз Инкорпорейтед Method for producing cycloalkylcarboxamido-indole compounds
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
CA2808501A1 (en) 2010-08-23 2012-03-01 Vertex Pharmaceuticals Incorporated Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
CN102133402B (en) * 2011-03-24 2013-06-12 首都医科大学附属北京同仁医院 Application of cystic fibrosis transmembrane transduction regulating factor inhibitor to preparation of medicaments for treating diabetes
WO2012153775A1 (en) 2011-05-10 2012-11-15 国立大学法人神戸大学 Thioxothiazolidine derivative having ras function inhibitory effect
US9254291B2 (en) 2011-11-08 2016-02-09 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
SMT201900451T1 (en) 2012-01-25 2019-11-13 Vertex Pharma Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US9012496B2 (en) 2012-07-16 2015-04-21 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
TWI736768B (en) 2012-11-02 2021-08-21 美商維泰克斯製藥公司 Pharmaceutical compositions for the treatment of cftr mediated diseases
FR2999191B1 (en) 2012-12-12 2016-02-05 Lesaffre & Cie PROBIOTIC STRAINS FOR THE TREATMENT AND / OR PREVENTION OF DIARRHEA
PT3131582T (en) 2014-04-15 2018-10-08 Vertex Pharma Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
PT3203840T (en) 2014-10-06 2020-10-27 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
CN104398509B (en) * 2014-11-13 2017-01-11 四川大学华西第二医院 Application of CFTR (cystic fibrosis transmembrane conductance regulator) inhibitor CFTRinh-172 in preparation of drug for prevention and treatment of leukemia cell mediated diseases
CN104788423B (en) * 2015-03-13 2016-10-26 成都理工大学 A kind of new cystic fibrosis transmembrane conductance regulator inhibitor
PT3394083T (en) 2015-12-24 2021-12-07 Univ California Cftr regulators and methods of use thereof
MX2021013639A (en) 2016-12-09 2022-09-30 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator.
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
MA51039A (en) 2017-12-08 2020-10-14 Vertex Pharma PROCESSES FOR PREPARING MODULATORS OF THE TRANSMEMBRANARY CONDUCTANCE REGULATOR OF MUCOVISCIDOSIS
BR112021025048A2 (en) * 2019-06-12 2022-02-01 Univ California Methods of treating bile acid diarrhea

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9010041B (en) * 1989-12-21 1992-08-26 Lilly Co Eli Compounds for treating inflammatory bowel disease
EP0728003A1 (en) * 1993-11-12 1996-08-28 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
UA56185C2 (en) * 1996-09-30 2003-05-15 Пфайзер Інк. Aralkyl- and aralkylidene heterocyclic lactams and imids, a pharmaceutical composition and a treatment method
US6423708B1 (en) * 1996-09-30 2002-07-23 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides
IL141456A0 (en) * 1998-08-21 2002-03-10 Viropharma Inc Rhodanine derivatives and pharmaceutical compositions containing the same
US6484397B1 (en) * 2000-07-11 2002-11-26 Corning Incorporated Method of assembling a catalytic converter for use in an internal combustion engine
US20020052396A1 (en) * 2001-04-23 2002-05-02 Bailey Thomas R. Compounds, compositions and methods for treating or preventing viral infections and associated diseases

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE HCAPLUS [online] GUPTA S.P. ET AL.: "Synthesis and fungitoxicity of some 5-sustituted 3-poly(nitrophenyl)rhodanines", XP002976975, accession no. STN Database accession no. 1978:597389 *
DATABASE HCAPLUS [online] MA T. ET AL.: "Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion", XP002976974, accession no. STN Database accession no. 2002:932809 *
DATABASE HCAPLUS [online] ROMAN O.M. ET AL.: "Synthesis and antiinflammatory activity of 3-aryl-5-arylidene-2-thioxothiazolidine-4-ones", XP002976976, accession no. STN Database accession no. 2002:664146 *
FARMATSEVTICHNII ZHURNAL (KIEV), vol. 3, 2002, pages 56 - 59 *
JOURNAL OF CLINICAL INVESTIGATION, vol. 110, no. 11, 2002, pages 1651 - 1658 *
JOURNAL OF THE INDIAN CHEMICAL SOCIETY, vol. 55, no. 5, 1978, pages 483 - 485 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8952049B2 (en) 2006-04-07 2015-02-10 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8952050B2 (en) 2006-04-07 2015-02-10 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters

Also Published As

Publication number Publication date
AU2003277162A1 (en) 2004-04-19
CA2500498A1 (en) 2004-04-08
JP4977319B2 (en) 2012-07-18
KR20050061501A (en) 2005-06-22
AU2003277162B2 (en) 2009-07-16
EP1549321A4 (en) 2007-05-23
CN100356922C (en) 2007-12-26
MXPA05003366A (en) 2005-10-05
AP2005003292A0 (en) 2005-06-30
NZ538809A (en) 2008-06-30
WO2004028480A2 (en) 2004-04-08
CA2500498C (en) 2012-08-21
EA009847B1 (en) 2008-04-28
CN1684686A (en) 2005-10-19
JP2006503853A (en) 2006-02-02
PL376147A1 (en) 2005-12-27
EP1549321A2 (en) 2005-07-06
AU2003277162C1 (en) 2009-12-24
BR0314943A (en) 2005-08-02
EA200500583A1 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
WO2004028480A3 (en) Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
WO2005094374A3 (en) Hydrazide-containing cftr inhibitor compounds and uses thereof
US20010031757A1 (en) Method for treating inflammatory diseases by administering a thrombin inhibitor
EP2210606A3 (en) Compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
WO2007126964A3 (en) Kinase inhibitors
WO2006133941A3 (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
WO2006053160A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
BRPI0413756A (en) compound, methods for treating or preventing spasticity or a symptom of spasticity, gastro-oesophageal reflux disease, drug addiction, alcohol addiction or abuse, or nicotine abuse or addiction, and cough or emesis in a patient, and, pharmaceutical composition
NO20053077L (en) Therapeutic formulations for the treatment of beta-amyloid-related diseases.
CA2566301A1 (en) Novel use of peptide compounds for treating essential tremor and other tremor syndromes
CN111902140A (en) Pharmaceutical composition for preventing or treating pruritus comprising HDAC6 inhibitor as active ingredient
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
WO2005044187A3 (en) Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
WO2004050025A3 (en) Combination of ibuprofen and oxycodone for acute pain relief
US6683054B1 (en) Use of melagatran
CA2389032A1 (en) Preventive or therapeutic agents for inflammatory diseases of intestine
EP1666064A4 (en) MEDICAMENT FOR TREATING DISEASES ASSOCIATED WITH TRANSLOCATION OF AN IMMUNOGLOBULIN GENE
Alqurashi et al. Protective effect of sterubin against neurochemical and behavioral impairments in rotenone-induced Parkinson's disease
UA92498C2 (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
CA2648751A1 (en) Use of aminapthone for the preparation of a medicament for treating arteriopathies
WO2005035500A3 (en) Therapeutic agents useful for treating pain
WO2005020968A3 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
JP4221267B2 (en) Drugs to suppress itching
AU2003248555A1 (en) Anti-cancer formulation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 167362

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 538809

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005/02517

Country of ref document: ZA

Ref document number: 2500498

Country of ref document: CA

Ref document number: 520/KOLNP/2005

Country of ref document: IN

Ref document number: 200502517

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1020057005551

Country of ref document: KR

Ref document number: 20038233665

Country of ref document: CN

Ref document number: 1-2005-500625

Country of ref document: PH

Ref document number: 2004540305

Country of ref document: JP

Ref document number: 376147

Country of ref document: PL

Ref document number: PA/a/2005/003366

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003277162

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: AP/P/2005/003292

Country of ref document: AP

WWE Wipo information: entry into national phase

Ref document number: 2003798805

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200500583

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 1200500594

Country of ref document: VN

WWP Wipo information: published in national office

Ref document number: 1020057005551

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003798805

Country of ref document: EP